|
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
Sep 2020 |
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors |
Jul 2024 |
PLOS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
Jun 2023 |
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
Jun 2020 |
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
|
Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates |
Jan 2019 |
Semin Hematol |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Genomics of myelodysplastic/myeloproliferative neoplasm |
May 2023 |
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
|
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
Jan 2021 |
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Paroxysmal Nocturnal Hemoglobinuria |
Jan 2024 |
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
Jul 2019 |
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
|
Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
